Literature DB >> 33345314

Ghrelin ameliorates nonalcoholic steatohepatitis induced by chronic low-grade inflammation via blockade of Kupffer cell M1 polarization.

Yue Yin1, Qin Wang1, Meiyuzhen Qi1, Chen Zhang1, Ziru Li1, Weizhen Zhang1,2.   

Abstract

Whether the stomach influences the progression of nonalcoholic steatohepatitis (NASH) remains largely unknown. Ghrelin, a 28-amino acid gastric hormone, is critical for the regulation of energy metabolism and inflammation. We investigated whether ghrelin affects the progression of NASH. NASH was induced with lipopolysaccharide (LPS; 240 μg/kg/day) in male C57BL/6J mice with high-fat diet (HFD). Ghrelin (11 nmol/kg/day) was administrated by a subcutaneous mini-pump. Liver steatosis, inflammation, and fibrosis were assessed. Kupffer cells and hepatocytes isolated from wild type, GHSR1a-/- or PPARγ+/- mice were cocultured to determine the cellular and molecular mechanism by which ghrelin ameliorates NASH. A low concentration of LPS activates the Kupffer cells, leading to the development of NASH in mice fed HFD. Ghrelin blocked the progression of NASH induced by LPS via GHSR1a-mediated attenuation of Kupffer cells M1 polarization. GHSR1a was detected in Kupffer cells isolated from wild-type mice but not in GHSR1a deficient animals. Upon binding with ghrelin, internalization of GHSR1a occurred. Ghrelin reduced levels of tumor necrosis factor-α and inducible nitricoxide synthase while increasing Arg1 in Kupffer cells treated with LPS. Ghrelin markedly attenuated the upregulation of lipid accumulation induced by the supernatant of Kupffer cells under both basal and LPS-treated conditions. Deficiency of PPARγ significantly reduced the effect of LPS on the hepatic steatosis in mice and in cultured hepatocytes. Our studies indicate that the stomach may improve the development of NASH via ghrelin. Ghrelin may serve as a marker and therapeutic target for NASH.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  NAFLD; PPARγ; X/A like cells; ghrelin; gut-liver interaction

Mesh:

Substances:

Year:  2020        PMID: 33345314      PMCID: PMC8026679          DOI: 10.1002/jcp.30218

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.513


  35 in total

1.  Good fat/bad fat.

Authors:  Craig J McClain; Shirish Barve; Ion Deaciuc
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

2.  Translating biased signaling in the ghrelin receptor system into differential in vivo functions.

Authors:  Franziska Mende; Cecilie Hundahl; Bianca Plouffe; Louise Julie Skov; Bjørn Sivertsen; Andreas Nygaard Madsen; Michael Lückmann; Thi Ai Diep; Stefan Offermanns; Thomas Michael Frimurer; Michel Bouvier; Birgitte Holst
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-09       Impact factor: 11.205

3.  Immune enhancing effect of a growth hormone secretagogue.

Authors:  G C Koo; C Huang; R Camacho; C Trainor; J T Blake; A Sirotina-Meisher; K D Schleim; T J Wu; K Cheng; R Nargund; G McKissick
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

4.  Ghrelin receptor expression in lymphocytes isolated from adult cystic fibrosis patients.

Authors:  Rubin I Cohen; Subani Chandra; Seth Koenig; Donna Tsang; David Wilson; Thomas McCloskey
Journal:  Respiration       Date:  2009-10-29       Impact factor: 3.580

5.  Exogenous ghrelin modulates release of pro-inflammatory and anti-inflammatory cytokines in LPS-stimulated macrophages through distinct signaling pathways.

Authors:  Talat Waseem; Mark Duxbury; Hiromichi Ito; Stanley W Ashley; Malcolm K Robinson
Journal:  Surgery       Date:  2007-12-27       Impact factor: 3.982

6.  Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria.

Authors:  Alejo Chorny; Per Anderson; Elena Gonzalez-Rey; Mario Delgado
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

7.  The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans.

Authors:  Sharmilee Gnanapavan; Blerina Kola; Stephen A Bustin; Damian G Morris; Patrick McGee; Peter Fairclough; Satya Bhattacharya; Robert Carpenter; Ashley B Grossman; Márta Korbonits
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

8.  Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis.

Authors:  Chantal A Rivera; Patrick Adegboyega; Nico van Rooijen; Arlene Tagalicud; Monique Allman; Matthew Wallace
Journal:  J Hepatol       Date:  2007-06-08       Impact factor: 25.083

Review 9.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Elena Buzzetti; Massimo Pinzani; Emmanuel A Tsochatzis
Journal:  Metabolism       Date:  2016-01-04       Impact factor: 8.694

10.  Growth hormone secretagogue receptor is important in the development of experimental colitis.

Authors:  Zhen-Ze Liu; Wei-Gang Wang; Qing Li; Miao Tang; Jun Li; Wen-Ting Wu; Ying-Han Wan; Zhu-Gang Wang; Shi-San Bao; Jian Fei
Journal:  Cell Biosci       Date:  2015-03-21       Impact factor: 7.133

View more
  7 in total

Review 1.  The Role of Autophagy and Pyroptosis in Liver Disorders.

Authors:  Huijie Zhao; Huiyang Liu; Yihan Yang; Honggang Wang
Journal:  Int J Mol Sci       Date:  2022-06-01       Impact factor: 6.208

Review 2.  Interaction between macrophages and ferroptosis.

Authors:  Yan Yang; Yu Wang; Lin Guo; Wen Gao; Ting-Li Tang; Miao Yan
Journal:  Cell Death Dis       Date:  2022-04-16       Impact factor: 9.685

Review 3.  Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor.

Authors:  Gianfabio Giorgioni; Fabio Del Bello; Wilma Quaglia; Luca Botticelli; Carlo Cifani; E Micioni Di Bonaventura; M V Micioni Di Bonaventura; Alessandro Piergentili
Journal:  J Med Chem       Date:  2022-02-14       Impact factor: 7.446

4.  Lower ghrelin levels does not impact the metabolic benefit induced by Roux-en-Y gastric bypass.

Authors:  Yuan Liang; Ruili Yu; Rui He; Lijun Sun; Chao Luo; Lu Feng; Hong Chen; Yue Yin; Weizhen Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-23       Impact factor: 6.055

Review 5.  Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?

Authors:  Vera Francisco; Maria Jesus Sanz; José T Real; Patrice Marques; Maurizio Capuozzo; Djedjiga Ait Eldjoudi; Oreste Gualillo
Journal:  Biology (Basel)       Date:  2022-08-19

Review 6.  Role of the Ghrelin System in Colitis and Hepatitis as Risk Factors for Inflammatory-Related Cancers.

Authors:  Aldona Kasprzak; Agnieszka Adamek
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

Review 7.  Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.

Authors:  Alvaro Santos-Laso; María Gutiérrez-Larrañaga; Marta Alonso-Peña; Juan M Medina; Paula Iruzubieta; María Teresa Arias-Loste; Marcos López-Hoyos; Javier Crespo
Journal:  Biomedicines       Date:  2021-12-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.